Enterprise Therapeutics, a spin-out of Sussex University set up to work on therapeutics aimed as respiratory diseases, has secured £1.6m ($2.4m) in a series A backed by Epidarex Capital.
The financing will go into funding drug discovery into the area, and will target diseases such as asthma, cystic fibrosis, and chronic obstructive pulmonary disease. Currently, many therapeutics in respiratory diseases combat the conditions by dilating airways or tackling inflammation. Enterprise will look at modifying key drivers of disease pathology, such as the mechanisms behind mucus congestion.
Martin Gosling, CSO of Enterprise Therapeutics, said: “We are delighted that Epidarex Capital has recognised the potential of Enterprise Therapeutics’ drug discovery approach and capabilities. We look forward to working together to discover and develop first in class therapies with the potential to impact the millions of patients with respiratory diseases.”
